Back
Cardiovascular Health
Astragaloside IV from Astragalus membranaceus showed cardioprotection during myocardial ischemia in vivo and in vitro.
Zhang, W. 2006
Astragaloside IV reduces inflammation in endothelial cells (cells in arterial walls).
Zhang 2003
Astragaloside IV inhibited vessel contraction through blocking calcium influx and intracellular calcium release.
Zhang, C. 2007
Bioavailability
The absolute bioavailability of astragaloside IV in rats after an oral dose was 2.2%.
Gu, Y. 2004
Fifty percent of Astragaloside IV administered via i.v. to rats was metabolized in vivo. The bioavailability was found to be 3.66%.
Du, Y. 2005
Astragaloside IV may have difficulty crossing the blood-brain barrier. The pharmokinetics of Astragaloside IV are 'favorable'.
Zhang 2006
The absolute bioavailability of AGS-IV after p.o. [oral] administration in Beagle dog was found to be 7.4%. There was no significant species difference regarding the pharmacokinetics of AGS-IV between the rat and the Beagle dog.
Zhang 2007
Chitosan and sodium deoxycholate can be used as absorption enhancers for Astragaloside IV.
Huang CR 2006
Other
Astragaloside (40 mg/kg, ig once a day for 10 weeks) markedly improved motor and memory dysfunction of D-gal-treated mice.
Lei H 2003
Astragalosides protect against ultraviolet A-induced photoaging in human fibroblasts.
Liu 2011
Know of a good study for Astragaloside IV but don't see it here? Add your own